NOTE. Percentage values in the cells may not sum up to 100% because of rounding. Bold indicates P < .05. Abbreviations: Bev, bevacizumab; ECOG-PS, Eastern Cooperative Oncology Group Performance Status ...
Redefining Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer in the Era of Novel Antibody-Drug Conjugates. If you have the appropriate software installed, you can download article ...
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the randomized Phase 2 FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant or everolimus ...
Pfizer (PFE) announced on Tuesday that its investigational breast cancer therapy, atirmociclib, as part of a combination regimen, reached the main goal in a mid-stage trial for certain patients with ...
In a new study, clinician-scientists and researchers from the National Cancer Centre Singapore (NCCS) have demonstrated the use of exosomes to successfully target squamous cell cancer tumours that are ...
Please provide your email address to receive an email when new articles are posted on . Phase 2a interim data show 100% of patients achieving the primary endpoint of skin toxicity improvement. Also, ...
Basel, March 20, 2026 – Novartis today announced that it has entered into an agreement with Synnovation Therapeutics, LLC to acquire SNV4818, a pan-mutant‑selective PI3Kα inhibitor, exploring a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results